
Exelixis has signed a licensing agreement with French biotech firm Ipsen for its cancer drug Cometriq (cabozantinib) for an upfront …

French pharma group Ipsen has snapped up privately-owned UK life sciences firm Syntaxin for an upfront payment of €28 million …
A new photodynamic therapy treatment for human papilloma virus (HPV) associated diseases of the cervix has shown potential in a …

Ipsen has appointed Claude Bertrand (pictured) chief scientific officer and Jacques-Pierre Moreau chief scientific advisor.Bertrand moves to the company next …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

